Adults aged ≥18 years with a risk condition are recommended to receive pneumococcal vaccine

A single dose of 21vPCV is recommended for people aged ≥18 years with a risk condition see Table. Risk conditions for pneumococcal vaccination and eligibility for NIP funding.

People who have previously received a dose of any pneumococcal vaccine (including 23vPPV [a pneumococcal polysaccharide vaccine], 13vPCV, 15vPCV, or 20vPCV) are recommended to receive this dose of 21vPCV at least 12 months after their last dose.

Children diagnosed with a risk condition before 18 years of age who received a dose of 20vPCV are recommended to receive a dose of 21vPCV at 18 years of age. See Infographic. Pneumococcal vaccination for people who have previously received a pneumococcal vaccine.

Adults aged ≥65 years and Aboriginal and Torres Strait Islander adults aged ≥25 years who develop a risk condition and have already received a 21vPCV as part of the adult program do not need another dose of 21vPCV.

People who have received a haematopoietic stem cell transplant are recommended to receive 3 doses of 21vPCV after transplantation regardless of pneumococcal vaccine history prior to undergoing HSCT. If an adult has commenced their post-HSCT schedule with 13vPCV, they are recommended to complete it with 21vPCV. If an adult has already completed their post-HSCT schedule with 13vPCV and two doses of 23vPPV or 20vPCV, then a single dose of 21vPCV is recommended. See Table. Recommendations for vaccination after haematopoietic stem cell transplant in children and adults.

21vPCV is funded through the NIP for people aged ≥18 years with certain risk conditions. See Table. Risk conditions for pneumococcal vaccination and eligibility for NIP funding For details see the National Immunisation Program Schedule.